Search Legislation

The Medicines for Human Use (Clinical Trials) Regulations 2004

 Help about what version

What Version

 Help about advanced features

Advanced Features

 Help about opening options

Opening OptionsExpand opening options

Changes over time for: Paragraph 9

 Help about opening options

Alternative versions:

Status:

Point in time view as at 06/11/2023.

Changes to legislation:

The Medicines for Human Use (Clinical Trials) Regulations 2004, Paragraph 9 is up to date with all changes known to be in force on or before 04 March 2025. There are changes that may be brought into force at a future date. Changes that have been made appear in the content and are referenced with annotations. Help about Changes to Legislation

9.  Where the holder of the authorisation has been informed by the licensing authority that any batch of any investigational medicinal product [F1or EAMS medicinal product] to which his authorisation relates has been found not to conform as regards strength, quality or purity with—U.K.

(a)the specification of the relevant product; or

(b)the provisions of these Regulations, [F2or the 2012 Regulations] that are applicable to the investigational medicinal product [F1or EAMS medicinal product],

he shall, if so directed, withhold such batch from distribution for use in clinical trials [F3or as part of the Early Access to Medicines Scheme], so far as may be reasonably practicable, for such a period not exceeding six weeks as may be specified by the licensing authority.

Back to top

Options/Help